• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home StudyGraphics

#VisualAbstract: Colchicine may lower the risk of cardiovascular events in patients with coronary disease

byConstance Wu
September 10, 2020
in StudyGraphics
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. Patients who received low-dose colchicine daily had a ~30% lower risk of cardiovascular events compared to those who received placebo.

2. Although the incidence of cardiovascular death was similar between groups, the colchicine group had a numerically greater number of non-cardiovascular deaths as well as all-cause deaths compared to the placebo group.

Evidence Rating Level: 1 (Excellent)

Study Rundown: Colchicine is an anti-inflammatory drug that exerts its effects through inhibition of microtubule assembly, thereby reducing inflammasome activation and modulating leukocyte responsiveness. The Colchicine Cardiovascular Outcomes Trial (COLCOT) found that daily use of colchicine soon after myocardial infarction reduced the risk of further ischemic cardiovascular events and the previous Low-Dose Colchicine (LoDoCo) pilot trial found that patients with stable coronary disease who received colchicine were significantly less likely to experience acute cardiovascular events compared to those who did not. This randomized, placebo-controlled trial, termed LoDoCo2, confirmed the association between colchicine use and decreased risk of cardiovascular events using a patient population that was roughly 10 times larger than the first. This benefit became detectable early in the study and persisted with no attenuation over 5 years of treatment. Adverse events such as cancer, infection, pneumonia, and gastrointestinal upset occurred at similar rates between groups. While not quite statistically significant, the incidence rate of non-cardiovascular death was higher in the colchicine group compared to placebo. This study circumvented many weaknesses of the original LoDoCo trial, including a small sample size and the lack of placebo control, but some limitations still remained, such as the lack of data on blood pressure, lipid levels, and biomarkers of inflammation. Overall, the results of the LoDoCo2 trial lend further support to the effectiveness of colchicine in reducing the occurrence of cardiovascular events in patients with chronic coronary disease.

Click here to read the study, published today in NEJM

Relevant Reading: Low-Dose Colchicine for Secondary Prevention of Cardiovascular Disease

In-Depth [randomized controlled trial]: In this multicenter study beginning in August 2014, 5222 patients between 35 and 82 years of age with evidence of coronary disease entered a 1-month open-label run-in phase before being randomly assigned in a 1:1 ratio to either continue receiving 0.5 mg colchicine daily or begin receiving placebo. Patients with moderate-to-severe renal impairment, severe heart failure, or severe valvular heart disease were excluded. The primary endpoint, a composite of cardiovascular death, spontaneous myocardial infarction, ischemic stroke, and ischemia-driven coronary revascularization, occurred in 187 patients (6.8%) in the colchicine group and 264 patients (9.6%) in the placebo group (incidence, 2.5 vs. 3.6 events, respectively, per 100 person-years; hazard ratio [HR], 0.69; 95% confidence interval [CI], 0.57 to 0.83; P<0.001). This effect was consistent across subgroups defined according to age, sex, smoking status, diabetes, renal function, hypertension, and statin dose. Between-group differences were also detected in the first five pre-ranked secondary endpoints, all of which were different combinations of the individual components noted above (P<0.01 for all). However, both groups had similar cardiovascular mortality (20 vs. 25 fatalities; HR, 0.80; 95% CI, 0.44 to 1.44), non-cardiovascular mortality (53 vs. 35 fatalities; HR, 1.51; 95% CI, 0.99 to 2.31), and all-cause mortality (incidence, 0.9 vs. 0.8 events, respectively, per 100 person-years; HR, 1.21; 95% CI, 0.86 to 1.71).

RELATED REPORTS

Poor sleep associated with lower cardiovascular disease-free life expectancy

History of adverse pregnancy outcomes associated with image-identified coronary artery disease

Empagliflozin use is associated with slower progression of chronic kidney disease

©2020 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: cardiovascularcardiovascular eventscardiovascular mortalitycardiovascular riskcolchicineCoronary artery disease
Previous Post

Angiotensin II infusion for refractory shock associated with improved hemodynamic stability and decreased vasopressor requirement

Next Post

#VisualAbstract: Proadrenomedullin predicts severe community-acquired pneumonia among children

RelatedReports

Sleep duration, sleepiness, chronotype have variable associations with teen self-regulation
Cardiology

Poor sleep associated with lower cardiovascular disease-free life expectancy

March 9, 2023
SARS-CoV-2 is associated with higher incidence of Kawasaki disease in children
Cardiology

History of adverse pregnancy outcomes associated with image-identified coronary artery disease

February 16, 2023
Fish oil and aspirin did not reduce arteriovenous fistula failure: The FAVOURED trail
Cardiology

Empagliflozin use is associated with slower progression of chronic kidney disease

January 26, 2023
UTI associated with increased risk of preeclampsia
Cardiology

Carotid and femoral bruits as cardiovascular risk indicators in a middle-aged Finnish population

December 13, 2022
Next Post
#VisualAbstract: Serum IL-6 and TNF-α levels identified as independent predictors of COVID-19 severity and mortality

#VisualAbstract: Proadrenomedullin predicts severe community-acquired pneumonia among children

Steroids and opioids often inappropriately prescribed in the emergency department for pediatric pneumonia and sinusitis

No significant differences in outcomes between pre- and post-treatment administration of P2Y12 inhibitors for NSTE-ACS

#VisualAbstract: Serum IL-6 and TNF-α levels identified as independent predictors of COVID-19 severity and mortality

#VisualAbstract: Serum IL-6 and TNF-α levels identified as independent predictors of COVID-19 severity and mortality

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Stroke may be associated with sleep disturbances in adults
  • Transcarotid artery revascularization not associated with a significant difference in 30-day risk of stroke, death and myocardial infarction compared to carotid endarterectomy
  • Drinking characteristics in adolescence predict alcohol behaviors in early adulthood
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

Want more physician-written
medical news?

Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.

Subscribe for free today!

Subscription options